Liraglutide

Shop Liraglutide
Code ths10 applied at checkout

Also called: PF-07976016 and Liraglutide, Liraglutide and Exercise, Oral Liraglutide Multi-Excipient System

By The Health Stacks Research TeamUpdated September 22, 2026

Liraglutide is a medicine that copies a natural body signal called GLP-1. It belongs to a group of drugs called GLP-1 medicines. Doctors give it to people with type 2 diabetes and to people who need help losing weight. It works by copying a gut hormone that comes out after you eat.

This helps the body make insulin, slows down how fast food leaves the stomach, and makes you feel full sooner. It is given as a daily shot. Studies show it helps lower blood sugar and helps with weight loss. Newer research suggests these medicines may do more than help with sugar and weight.

In one big study, liraglutide was given to more than 2,600 people with asthma or lung disease, and people taking GLP-1 medicines had fewer breathing flare-ups than people taking older diabetes pills. Other studies suggest benefits for gut and mental health problems too. But much of this research is very new and still being checked. Liraglutide is a real prescription drug, so it should only be used with a doctor's care.

ApprovedApproved by a regulator (e.g. FDA) for a specific medical use — the highest research-status tier. Verified confidence80–100 — backed by strong, well-corroborated sources (peer-reviewed research, clinical guidelines). Our highest confidence tier.

Benefits

What Liraglutide Helps With

The benefits people report — backed by research.

Glycemic & metabolic (61)

Improved blood glucose control in type 2 diabetes 90/100Rated 90/100Source typeRegulator or clinical registryIndependent sources12Every claim links to the page it came from, and stronger sources rate higher. Full methodology →· 12 srcSuperior blood glucose control compared to individual components 90/100Rated 90/100Source typeRegulator or clinical registryIndependent sources11Every claim links to the page it came from, and stronger sources rate higher. Full methodology →· 11 srcGlycemic Control in Type 2 Diabetes 95/100Rated 95/100Source typePeer-reviewed studyIndependent sources4Every claim links to the page it came from, and stronger sources rate higher. Full methodology →· 4 srcAngiogenesis 95/100Rated 95/100Source typePeer-reviewed studyIndependent sources4Every claim links to the page it came from, and stronger sources rate higher. Full methodology →· 4 srcSuperior HbA1c reduction compared to individual components 90/100Rated 90/100Source typeRegulator or clinical registryIndependent sources4Every claim links to the page it came from, and stronger sources rate higher. Full methodology →· 4 srcImproved glycaemic control in type 2 diabetes 90/100Rated 90/100Source typeRegulator or clinical registryIndependent sources3Every claim links to the page it came from, and stronger sources rate higher. Full methodology →· 3 srcTreatment of Type 2 Diabetes 72/100Rated 72/100Source typeEstablished referenceIndependent sources3Every claim links to the page it came from, and stronger sources rate higher. Full methodology →· 3 srcReduces HbA1c in adults with type 2 diabetes 90/100Rated 90/100Source typeRegulator or clinical registryIndependent sources2Every claim links to the page it came from, and stronger sources rate higher. Full methodology →· 2 srcEffective HbA1c reduction in type 2 diabetes patients inadequately controlled on oral medications 90/100Rated 90/100Source typeRegulator or clinical registryIndependent sources2Every claim links to the page it came from, and stronger sources rate higher. Full methodology →· 2 srcEffective when oral medications or GLP-1 agonists alone fail 90/100Rated 90/100Source typeRegulator or clinical registryIndependent sources2Every claim links to the page it came from, and stronger sources rate higher. Full methodology →· 2 srcImprovement of glycemic control in T2D via pancreatic GLP-1R activation 95/100Rated 95/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Dose-dependent reduction of glycemic levels 95/100Rated 95/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Longer duration of antihyperglycemic action compared to exendin-4 95/100Rated 95/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Marked antihyperglycemic effects in rodent models of beta-cell deficiencies 95/100Rated 95/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Therapeutic use as a hypoglycemic agent in type 2 diabetes 95/100Rated 95/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Therapeutic use as a hypoglycemic agent in type 2 diabetes mellitus 95/100Rated 95/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Insulin sensitivity 95/100Rated 95/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Glycemic Control Improvement 95/100Rated 95/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Reduction in risk of progression from prediabetes to type 2 diabetes mellitus 95/100Rated 95/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →GLP-1 RAs approved as adjunctive therapy to improve glycemic control in type 2 diabetes mellitus 95/100Rated 95/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Glycaemic Control 90/100Rated 90/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Effective replacement of GLP-1 agonist therapy 90/100Rated 90/100Source typeRegulator or clinical registryIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Effective HbA1c reduction in inadequately controlled type 2 diabetes 90/100Rated 90/100Source typeRegulator or clinical registryIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Reduces HbA1c in type 2 diabetes 90/100Rated 90/100Source typeRegulator or clinical registryIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Reduces HbA1c for blood glucose control in type 2 diabetes 90/100Rated 90/100Source typeRegulator or clinical registryIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Reduces HbA1c in adolescents and children with type 2 diabetes 90/100Rated 90/100Source typeRegulator or clinical registryIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Reduces HbA1c as monotherapy more effectively than glimepiride 90/100Rated 90/100Source typeRegulator or clinical registryIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Reduces HbA1c by approximately 1 percentage point in dual therapy with metformin or glimepiride 90/100Rated 90/100Source typeRegulator or clinical registryIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Reduces HbA1c by 1.3 to 1.5 percentage points in triple therapy combinations 90/100Rated 90/100Source typeRegulator or clinical registryIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Effective at reducing HbA1c in adolescents and children aged 10 and above 90/100Rated 90/100Source typeRegulator or clinical registryIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Improves glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes 90/100Rated 90/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Effective when oral diabetes medicines or GLP-1 agonists fail to provide adequate control 90/100Rated 90/100Source typeRegulator or clinical registryIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Reduces symptoms and complications of diabetes 90/100Rated 90/100Source typeRegulator or clinical registryIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Effective when oral medications or GLP-1 agonists alone fail to control glucose 90/100Rated 90/100Source typeRegulator or clinical registryIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Effective when prior oral or injectable diabetes medicines fail 90/100Rated 90/100Source typeRegulator or clinical registryIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Effective when oral diabetes medicines or GLP-1 agonists fail 90/100Rated 90/100Source typeRegulator or clinical registryIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Preservation of islet mass during culture 90/100Rated 90/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Temporary increase in beta-cell mass 90/100Rated 90/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Significantly increases beta-cell mass in diabetic animals 90/100Rated 90/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Reduces food intake contributing to lower blood glucose 90/100Rated 90/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Significantly reduces time-to-normoglycemia after marginal mass islet transplant 90/100Rated 90/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →GLP-1 receptor agonists lower blood pressure in type 2 diabetes mellitus 90/100Rated 90/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Lower risk of early death in people with type 2 diabetes 90/100Rated 90/100Source typeRegulator or clinical registryIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Decrease the risk of progression to Type 2 Diabetes Mellitus 90/100Rated 90/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Improved human islet engraftment post-transplantation 85/100Rated 85/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Lower risk of diabetes, heart disease, stroke, high blood pressure 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Brain / cognitive 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →GLP-1 peptides liraglutide and semaglutide are marketed for the treatment of type 2 diabetes 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Controlling iron concentration below 2 µg/g during production and formulation minimizes HMWP formation, stabilizing GLP-1 compositions 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Genetically proxied GLP1R agonist significantly associated with decreased risk of diabetic nephropathy and IgA nephropathy 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Improved blood glucose control 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Improves glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Improvement in metabolic outcomes 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Lowering blood glucose levels 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Improvement in cardiometabolic parameters 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Significant improvement in glycemic control for type 2 diabetes 60/100Rated 60/100Source typeSpecialist communityIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Improves pancreatic beta-cell function and increases beta-cell mass 60/100Rated 60/100Source typeSpecialist communityIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Improved glycemic control and HbA1c reduction in type 2 diabetes 60/100Rated 60/100Source typeSpecialist communityIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Reduced progression from prediabetes to type 2 diabetes 60/100Rated 60/100Source typeSpecialist communityIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Liraglutide reduces progression from prediabetes to type 2 diabetes by 79% 60/100Rated 60/100Source typeSpecialist communityIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Liraglutide reduced MACE by 13% in high-risk type 2 diabetes 60/100Rated 60/100Source typeSpecialist communityIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →

Weight management (39)

Weight management 95/100Rated 95/100Source typePeer-reviewed studyIndependent sources12Every claim links to the page it came from, and stronger sources rate higher. Full methodology →· 12 srcReduces BMI in adolescents 90/100Rated 90/100Source typeRegulator or clinical registryIndependent sources7Every claim links to the page it came from, and stronger sources rate higher. Full methodology →· 7 srcBMI reduction in adolescents 90/100Rated 90/100Source typeRegulator or clinical registryIndependent sources6Every claim links to the page it came from, and stronger sources rate higher. Full methodology →· 6 srcBMI reduction in children 90/100Rated 90/100Source typeRegulator or clinical registryIndependent sources5Every claim links to the page it came from, and stronger sources rate higher. Full methodology →· 5 srcReduces BMI in children 90/100Rated 90/100Source typeRegulator or clinical registryIndependent sources5Every claim links to the page it came from, and stronger sources rate higher. Full methodology →· 5 srcBMI reduction in adolescents with obesity 90/100Rated 90/100Source typeRegulator or clinical registryIndependent sources3Every claim links to the page it came from, and stronger sources rate higher. Full methodology →· 3 srcBMI reduction in children with obesity 90/100Rated 90/100Source typeRegulator or clinical registryIndependent sources3Every claim links to the page it came from, and stronger sources rate higher. Full methodology →· 3 srcReduction in BMI for pediatric and adolescent patients with obesity 90/100Rated 90/100Source typeRegulator or clinical registryIndependent sources2Every claim links to the page it came from, and stronger sources rate higher. Full methodology →· 2 srcReduces BMI in pediatric patients 90/100Rated 90/100Source typeRegulator or clinical registryIndependent sources2Every claim links to the page it came from, and stronger sources rate higher. Full methodology →· 2 srcTreatment of Obesity 72/100Rated 72/100Source typeEstablished referenceIndependent sources2Every claim links to the page it came from, and stronger sources rate higher. Full methodology →· 2 srcAppetite suppression 70/100Rated 70/100Source typeEstablished referenceIndependent sources2Every claim links to the page it came from, and stronger sources rate higher. Full methodology →· 2 srcReduction in Waist Circumference 95/100Rated 95/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Reduction in Visceral Adipose Tissue 95/100Rated 95/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Brain / cognitive 95/100Rated 95/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Treatment of obesity associated with genetic syndromes 90/100Rated 90/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Appetite suppression via GLP-1 receptor agonism 90/100Rated 90/100Source typeRegulator or clinical registryIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Reduction in BMI for adolescents with obesity 90/100Rated 90/100Source typeRegulator or clinical registryIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Reduction in BMI for children with obesity 90/100Rated 90/100Source typeRegulator or clinical registryIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Appetite suppression and increased feeling of fullness 90/100Rated 90/100Source typeRegulator or clinical registryIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Reduces BMI in children with obesity 90/100Rated 90/100Source typeRegulator or clinical registryIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →BMI reduction in pediatric patients 90/100Rated 90/100Source typeRegulator or clinical registryIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Reduction in BMI for pediatric and adolescent patients 90/100Rated 90/100Source typeRegulator or clinical registryIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Reduces BMI in obese adolescents 90/100Rated 90/100Source typeRegulator or clinical registryIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Reduces BMI in obese children 90/100Rated 90/100Source typeRegulator or clinical registryIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Suppresses appetite and increases feeling of fullness via GLP-1 receptor agonism 90/100Rated 90/100Source typeRegulator or clinical registryIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Effective in patients uncontrolled on GLP-1 agonist therapy 90/100Rated 90/100Source typeRegulator or clinical registryIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Oral semaglutide formulation may improve treatment adherence 85/100Rated 85/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Liraglutide increased IVF pregnancy rates in obese PCOS women with poor response to first-line reproductive treatments 85/100Rated 85/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Reduction of appetite 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Insulin sensitivity 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Avexitide shows consistent, dose-dependent reductions in hypoglycemic events in post-bariatric hypoglycemia 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Appetite regulation via GLP-1 receptor agonism 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Targets appetite, satiety and reward pathways 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Enables adherence to healthy lifestyle 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Reduction in BMI z-scores 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Angiogenesis 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Liraglutide is a widely prescribed medication for both type 2 diabetes and obesity since its 2010 approval 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Appetite suppression and satiety enhancement 60/100Rated 60/100Source typeSpecialist communityIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Generic liraglutide is available since 2024 60/100Rated 60/100Source typeSpecialist communityIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →

Cardiovascular & vascular (8)

Angiogenesis 95/100Rated 95/100Source typePeer-reviewed studyIndependent sources13Every claim links to the page it came from, and stronger sources rate higher. Full methodology →· 13 srcExerts antihypertensive actions and reduces blood pressure 95/100Rated 95/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Promotes the secretion of atrial natriuretic peptide 95/100Rated 95/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Improvements in blood pressure, lipids, and beta-cell function 90/100Rated 90/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Directly binds to Transthyretin protein 85/100Rated 85/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Reduces risk of heart attack, stroke, and heart-related death 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Cardiometabolic risk reduction 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →GLP-1 receptor agonists confer cardioprotective effects in experimental myocardial infarction via Tie2+ cell GLP-1 receptors 60/100Rated 60/100Source typeSpecialist communityIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →

Renal & hepatic (5)

Increases urine sodium excretion 95/100Rated 95/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Improvement of macroalbuminuria in patients with chronic kidney disease 95/100Rated 95/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Improvement in renal outcomes 95/100Rated 95/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Reduce risk of heart and kidney complications 90/100Rated 90/100Source typeRegulator or clinical registryIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Kidney function protection 70/100Rated 70/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →

Gastrointestinal & gut (4)

Brain / cognitive 95/100Rated 95/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Trace-metal/reducing-agent systems combined with PEs increase intestinal absorption 80/100Rated 80/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Gastric / gut lining 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Insulin sensitivity 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →

Neuroprotection & cognitive (4)

Reduction of nicotine-induced conditioned place preference 85/100Rated 85/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Brain / cognitive 85/100Rated 85/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Improvement in learning and memory tasks 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Reduction of amyloid and tau deposits 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →

Musculoskeletal (4)

Muscle recovery 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Reduced pain and cartilage degradation in osteoarthritis 70/100Rated 70/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Reduction of testosterone levels 60/100Rated 60/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Liraglutide 16-week study increased testosterone in males with obesity-related low testosterone 60/100Rated 60/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →

Immune modulation (3)

Treatment of GPIHBP1 Autoantibody Syndrome 90/100Rated 90/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Beneficial impact on the engraftment and function of syngeneic islet transplants 85/100Rated 85/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Angiogenesis 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →

More reported benefits (18)

Impact on comorbidities 95/100Rated 95/100Source typePeer-reviewed studyIndependent sources2Every claim links to the page it came from, and stronger sources rate higher. Full methodology →· 2 srcReduction in Psoriasis Area and Severity Index scores 72/100Rated 72/100Source typeEstablished referenceIndependent sources2Every claim links to the page it came from, and stronger sources rate higher. Full methodology →· 2 srcImprovement in health indicators 95/100Rated 95/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Reduces albuminuria 95/100Rated 95/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →ApoA1 Proteome Improvement 95/100Rated 95/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Prevention of hospital admissions for heart failure 95/100Rated 95/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →FDA comprehensive review found no increased risk of suicidal ideation or behavior with GLP-1 RA use; FDA requesting removal of SI/B warning from labeling 95/100Rated 95/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →No increased risk of suicidal ideation or behavior associated with GLP-1 RA use per comprehensive FDA review 95/100Rated 95/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →FDA comprehensive review found no increased risk of suicidal ideation/behavior with GLP-1 RA use 95/100Rated 95/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Liraglutide with SDS plus zinc-iron reducing system increased rodent AUC ~42-fold vs SDS alone 80/100Rated 80/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Reduced composite endpoint by 13% vs placebo in LEADER trial, absolute risk reduction 1.9% 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Liraglutide achieves ~4.5-6.8% TBWL vs placebo 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Liraglutide's C-16 palmitoyl fatty acid side chain enables albumin binding, prolonging action 60/100Rated 60/100Source typeSpecialist communityIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Liraglutide is a GLP-1 receptor agonist with 97% homology to native GLP-1 and a C-16 palmitoyl fatty acid side chain enabling albumin binding 60/100Rated 60/100Source typeSpecialist communityIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Anti-inflammatory 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Targeted cancer cell killing in ovarian cancer 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Combination tesamorelin and GLP-1 receptor agonist therapy highly effective in reducing both excess visceral abdominal fat and obesity in people with HIV 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Sleep 70/100Rated 70/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →

Free: The Peptide Stack Cheat-Sheet

You just read the research on Liraglutide. The cheat-sheet maps the most-used peptide stacks — doses, timing, and what to check before buying — on one page.

No spam. Unsubscribe anytime.

How People Use It

1 reported routine — each line links to the source it came from.

From published sources

Routines as reported in peer-reviewed papers, clinical guidance, or vetted media — each linked to the source it came from.

SubQ

  • 0.6 mg daily (Week 1), 1.2 mg daily (Standard), 1.8 mg daily (Max) 95/100Rated 95/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ source

mg vs mcg: one milligram (mg) equals 1,000 micrograms (mcg) — multiply by 1,000 going from mg to mcg, divide by 1,000 going from mcg to mg. Mixing the two up is a thousand-fold dosing error: 1 mg taken instead of 1 mcg is a 1,000× overdose; 1 mcg instead of 1 mg is a 1,000× underdose. Always double-check the unit label and the decimal place.

Safety

Known Side Effects

Adverse effects reported in the research and by community use.

  • Anaphylactic shock (Taspoglutide)LifeThreatening 95/100Rated 95/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ doi.org
  • Pancreatitis (not observed / no induction)Mild 95/100Rated 95/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ ncbi.nlm.nih.gov
  • Initial reduction in food intakeMild 95/100Rated 95/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ ncbi.nlm.nih.gov
  • Asymptomatic elevated pancreatic enzymes (lipase and amylase)Mild 95/100Rated 95/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ ncbi.nlm.nih.gov
  • NauseaMildReported in 96 sources 90/100Rated 90/100Source typeRegulator or clinical registryIndependent sources96Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ ema.europa.eu↗ fda.gov↗ ema.europa.eu↗ ema.europa.eu+92
  • DiarrhoeaMildReported in 67 sources 90/100Rated 90/100Source typeRegulator or clinical registryIndependent sources67Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ ema.europa.eu↗ ema.europa.eu↗ ema.europa.eu↗ ema.europa.eu+63
  • HypoglycaemiaModerateReported in 3 sources 90/100Rated 90/100Source typeRegulator or clinical registryIndependent sources3Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ ema.europa.eu↗ ema.europa.eu↗ diabetes.co.uk
  • Decreased appetiteMildReported in 6 sources 90/100Rated 90/100Source typePeer-reviewed studyIndependent sources6Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ fda.gov↗ fda.gov↗ medlineplus.gov↗ singlecare.com+2
  • DyspepsiaMildReported in 2 sources 90/100Rated 90/100Source typePeer-reviewed studyIndependent sources2Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ fda.gov↗ fda.gov
  • Acute cholecystitisSevere 90/100Rated 90/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ fda.gov
  • Hypersensitivity reactionSevere 90/100Rated 90/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ fda.gov
  • Hypoglycaemia (low blood glucose)ModerateReported in 38 sources 90/100Rated 90/100Source typeRegulator or clinical registryIndependent sources38Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ ema.europa.eu↗ ema.europa.eu↗ ema.europa.eu↗ ema.europa.eu+34
  • Nausea (feeling sick)MildReported in 2 sources 90/100Rated 90/100Source typeRegulator or clinical registryIndependent sources2Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ ema.europa.eu↗ ema.europa.eu
  • Dyspepsia (indigestion)MildReported in 16 sources 90/100Rated 90/100Source typeRegulator or clinical registryIndependent sources16Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ ema.europa.eu↗ ema.europa.eu↗ ema.europa.eu↗ ema.europa.eu+12
  • Gastritis (inflammation of the stomach)ModerateReported in 16 sources 90/100Rated 90/100Source typeRegulator or clinical registryIndependent sources16Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ ema.europa.eu↗ ema.europa.eu↗ ema.europa.eu↗ ema.europa.eu+12
  • Abdominal pain (stomach ache)MildReported in 11 sources 90/100Rated 90/100Source typeRegulator or clinical registryIndependent sources11Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ ema.europa.eu↗ ema.europa.eu↗ ema.europa.eu↗ ema.europa.eu+7
  • Flatulence (wind)MildReported in 11 sources 90/100Rated 90/100Source typeRegulator or clinical registryIndependent sources11Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ ema.europa.eu↗ ema.europa.eu↗ ema.europa.eu↗ ema.europa.eu+7
  • Gastroesophageal reflux diseaseMildReported in 16 sources 90/100Rated 90/100Source typeRegulator or clinical registryIndependent sources16Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ ema.europa.eu↗ ema.europa.eu↗ ema.europa.eu↗ ema.europa.eu+12
  • Distension (swelling) of the bellyMildReported in 15 sources 90/100Rated 90/100Source typeRegulator or clinical registryIndependent sources15Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ ema.europa.eu↗ ema.europa.eu↗ ema.europa.eu↗ ema.europa.eu+11
  • Renal impairment or kidney failureSevereReported in 2 sources 90/100Rated 90/100Source typePeer-reviewed studyIndependent sources2Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ fda.gov↗ theepochtimes.com
  • HypersensitivitySevere 90/100Rated 90/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ fda.gov
  • Thyroid tumors / Thyroid cancer riskSevere 90/100Rated 90/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ medlineplus.gov
  • Severe nausea and vomiting (Overdose)Severe 90/100Rated 90/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ medlineplus.gov
  • Depression and suicidal thoughtsSevere 90/100Rated 90/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ medlineplus.gov
  • Allergic reactionSevere 90/100Rated 90/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ medlineplus.gov
  • HeartburnMild 90/100Rated 90/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ medlineplus.gov
  • FlatulenceMildReported in 5 sources 90/100Rated 90/100Source typeRegulator or clinical registryIndependent sources5Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ ema.europa.eu↗ ema.europa.eu↗ ema.europa.eu↗ ema.europa.eu+1
  • Distension of the bellyMild 90/100Rated 90/100Source typeRegulator or clinical registryIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ ema.europa.eu
  • Potential adverse effects on thyroid C-cells (monitored via calcitonin)Moderate 90/100Rated 90/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ ncbi.nlm.nih.gov
  • Reduced beta cell massModerate 85/100Rated 85/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ ncbi.nlm.nih.gov
  • Reduced alpha cell massModerate 85/100Rated 85/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ ncbi.nlm.nih.gov
  • Chemically induced pancreatitisSevere 85/100Rated 85/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ ncbi.nlm.nih.gov
  • Adverse effects of LiraglutideMild 85/100Rated 85/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ ncbi.nlm.nih.gov
  • DizzinessMildReported in 5 sources 72/100Rated 72/100Source typeEstablished referenceIndependent sources5Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ singlecare.com↗ singlecare.com↗ saxenda.com↗ ncoa.org+1
  • HypoglycemiaModerateReported in 10 sources 72/100Rated 72/100Source typeEstablished referenceIndependent sources10Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ fda.gov↗ fda.gov↗ singlecare.com↗ singlecare.com+6
  • Injection site reactionMildReported in 4 sources 72/100Rated 72/100Source typeEstablished referenceIndependent sources4Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ singlecare.com↗ singlecare.com↗ saxenda.com↗ pdr.net
  • FatigueMildReported in 2 sources 72/100Rated 72/100Source typeEstablished referenceIndependent sources2Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ singlecare.com↗ saxenda.com
  • Abdominal painModerateReported in 6 sources 72/100Rated 72/100Source typeEstablished referenceIndependent sources6Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ ema.europa.eu↗ ema.europa.eu↗ ema.europa.eu↗ ema.europa.eu+2
  • Acute pancreatitisSevereReported in 4 sources 72/100Rated 72/100Source typeEstablished referenceIndependent sources4Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ singlecare.com↗ peptidedeck.com↗ rheumatologyadvisor.com↗ ro.co
  • Gallbladder diseaseSevereReported in 5 sources 72/100Rated 72/100Source typeEstablished referenceIndependent sources5Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ medlineplus.gov↗ singlecare.com↗ singlecare.com↗ peptidepedia.org+1
  • Renal failureLifeThreateningReported in 3 sources 72/100Rated 72/100Source typeEstablished referenceIndependent sources3Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ fda.gov↗ singlecare.com↗ singlecare.com
  • Suicidal ideationSevereReported in 2 sources 72/100Rated 72/100Source typeEstablished referenceIndependent sources2Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ singlecare.com↗ pdr.net
  • Hypersensitivity reactionsLifeThreateningReported in 2 sources 72/100Rated 72/100Source typeEstablished referenceIndependent sources2Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ singlecare.com↗ theepochtimes.com
  • Thyroid C-cell tumorsLifeThreateningReported in 7 sources 72/100Rated 72/100Source typeEstablished referenceIndependent sources7Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ fda.gov↗ fda.gov↗ singlecare.com↗ singlecare.com+3
  • Upper respiratory infectionMild 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ singlecare.com
  • CholecystitisSevere 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ singlecare.com
  • AnaphylaxisLifeThreatening 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ singlecare.com
  • Stomach painMildReported in 3 sources 72/100Rated 72/100Source typeEstablished referenceIndependent sources3Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ singlecare.com↗ saxenda.com↗ incarenow.com
  • Sore throat and runny noseMild 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ singlecare.com
  • Gallbladder problemsSevereReported in 2 sources 72/100Rated 72/100Source typeEstablished referenceIndependent sources2Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ singlecare.com↗ yalemedicine.org
  • Kidney failureLifeThreatening 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ singlecare.com
  • Serious allergic reactionsLifeThreateningReported in 2 sources 72/100Rated 72/100Source typeEstablished referenceIndependent sources2Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ singlecare.com↗ saxenda.com
  • Bullous pemphigoidModerateReported in 2 sources 72/100Rated 72/100Source typeEstablished referenceIndependent sources2Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ endocrinologyadvisor.com↗ dermatologyadvisor.com
  • Eosinophilic panniculitisModerateReported in 2 sources 72/100Rated 72/100Source typeEstablished referenceIndependent sources2Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ endocrinologyadvisor.com↗ dermatologyadvisor.com
  • Morbilliform eruptionsMildReported in 2 sources 72/100Rated 72/100Source typeEstablished referenceIndependent sources2Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ endocrinologyadvisor.com↗ dermatologyadvisor.com
  • Fixed drug eruptionsModerateReported in 2 sources 72/100Rated 72/100Source typeEstablished referenceIndependent sources2Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ endocrinologyadvisor.com↗ dermatologyadvisor.com
  • Dermal hypersensitivityModerateReported in 2 sources 72/100Rated 72/100Source typeEstablished referenceIndependent sources2Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ endocrinologyadvisor.com↗ dermatologyadvisor.com
  • AlopeciaMild 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ endocrinologyadvisor.com
  • Injection-site reactions (erythemaMildReported in 2 sources 72/100Rated 72/100Source typeEstablished referenceIndependent sources2Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ endocrinologyadvisor.com↗ dermatologyadvisor.com
  • NauseaModerate 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ singlecare.com
  • Hypoglycemia (low blood sugar)ModerateReported in 4 sources 72/100Rated 72/100Source typeEstablished referenceIndependent sources4Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ medlineplus.gov↗ singlecare.com↗ saxenda.com↗ ro.co
  • Hair lossMild 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ singlecare.com
  • Thyroid C-cell tumors riskSevere 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ singlecare.com
  • Suicidal thoughts and behaviorsSevere 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ singlecare.com
  • Enhanced immunogenicity from HMWP in GLP-1 drug productsModerate 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ patents.google.com
  • Altered subcutaneous absorption kinetics from HMWPModerate 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ patents.google.com
  • Enhanced injection site toxicity from HMWPModerate 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ patents.google.com
  • Diminished biopotency from HMWPMild 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ patents.google.com
  • Skeletal muscle mass lossModerate 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ synapse.patsnap.com
  • Subcutaneous adipose gainMild 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ synapse.patsnap.com
  • Gastrointestinal side effectsModerateReported in 2 sources 72/100Rated 72/100Source typeEstablished referenceIndependent sources2Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ aspe.hhs.gov↗ singlecare.com
  • Gastrointestinal eventsModerate 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ synapse.patsnap.com
  • Hypoglycemia eventsModerate 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ synapse.patsnap.com
  • NasopharyngitisMildReported in 2 sources 72/100Rated 72/100Source typeEstablished referenceIndependent sources2Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ singlecare.com↗ healio.com
  • Reduced appetiteMild 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ singlecare.com
  • Thyroid C-cell tumors (Medullary thyroid cancer)LifeThreatening 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ singlecare.com
  • Indigestion (dyspepsia)Mild 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ singlecare.com
  • Kidney impairment or kidney failureSevere 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ singlecare.com
  • rashMild 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ endocrinologyadvisor.com
  • subcutaneous nodules)Mild 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ endocrinologyadvisor.com
  • VomitingModerate 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ singlecare.com
  • DiarrheaModerate 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ singlecare.com
  • and constipationModerate 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ singlecare.com
  • Psychiatric disordersSevere 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ nature.com
  • Major depressionSevere 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ nature.com
  • AnxietyModerate 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ nature.com
  • Suicidal behaviorLifeThreatening 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ nature.com
  • Depressive symptomsSevere 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ nature.com
  • InsomniaMild 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ nature.com
  • NervousnessMild 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ nature.com
  • Food aversionMild 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ nature.com
  • Liraglutide GI event incidence 53% vs 8%Mild 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ nature.com
  • Vomiting (liraglutide, orforglipron, semaglutide, tirzepatide)Moderate 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ nature.com
  • Upper abdominal pain (liraglutide, semaglutide)Mild 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ nature.com
  • Abdominal pain (liraglutide, semaglutide, tirzepatide)Moderate 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ nature.com
  • Memory and language problemsModerate 70/100Rated 70/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ webmd.com
  • DepressionModerate 70/100Rated 70/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ webmd.com
  • Nausea and vomitingModerate 60/100Rated 60/100Source typeSpecialist communityIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ glucagon.com
  • Headaches and dizzinessMild 60/100Rated 60/100Source typeSpecialist communityIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ glucagon.com
  • Elevated heart rateMild 60/100Rated 60/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ singlecare.com

Reported in research and community sources — not exhaustive. Discontinue use and consult a healthcare professional if side effects occur.

Get Liraglutide

Compare research-grade suppliers with third-party COAs and published purity data. For in-vitro and laboratory research use only — not for human consumption, diagnosis, or treatment.

Shop Liraglutide
Code ths10 applied at checkout

Evidence

Research Citations (21)

Every claim above traces back to a source you can check — here are 21 of them.

  • Effectiveness of dulaglutide vs liraglutide and exenatide once-weekly. A real-world study and meta-analysis of observational studies.

    2020 95/100Rated 95/100Source typePeer-reviewed studyIndependent sourcesstill being verifiedEvery claim links to the page it came from, and stronger sources rate higher. Full methodology →
    Source

  • Exenatide and liraglutide: different approaches to develop GLP-1 receptor agonists (incretin mimetics)--preclinical and clinical results.

    2009 95/100Rated 95/100Source typePeer-reviewed studyIndependent sourcesstill being verifiedEvery claim links to the page it came from, and stronger sources rate higher. Full methodology →
    Source

  • Liraglutide and Renal Outcomes in Type 2 Diabetes.

    2017 95/100Rated 95/100Source typePeer-reviewed studyIndependent sourcesstill being verifiedEvery claim links to the page it came from, and stronger sources rate higher. Full methodology →
    Source

  • A meta-analysis of serious adverse events reported with exenatide and liraglutide: acute pancreatitis and cancer.

    2012 95/100Rated 95/100Source typePeer-reviewed studyIndependent sourcesstill being verifiedEvery claim links to the page it came from, and stronger sources rate higher. Full methodology →
    Source

  • Pancreatic Effects of Liraglutide or Sitagliptin in Overweight Patients With Type 2 Diabetes: A 12-Week Randomized, Placebo-Controlled Trial.

    2017 95/100Rated 95/100Source typePeer-reviewed studyIndependent sourcesstill being verifiedEvery claim links to the page it came from, and stronger sources rate higher. Full methodology →
    Source

  • Liraglutide protects against nonalcoholic fatty liver disease in ApoE knockout mice with high-fat diet and silenced Acrp30 by increasing AMPK

    2014 95/100Rated 95/100Source typePeer-reviewed studyIndependent sourcesstill being verifiedEvery claim links to the page it came from, and stronger sources rate higher. Full methodology →
    Source

  • Weight loss and treatment patterns in a real-world population of adults receiving liraglutide 3.0 mg for weight management in routine clinical practice in Switzerland (ADDRESS study).

    2024 95/100Rated 95/100Source typePeer-reviewed studyIndependent sourcesstill being verifiedEvery claim links to the page it came from, and stronger sources rate higher. Full methodology →
    Source

  • Liraglutide improves memory in obese patients with prediabetes or early type 2 diabetes: a randomized, controlled study.

    95/100Rated 95/100Source typePeer-reviewed studyIndependent sourcesstill being verifiedEvery claim links to the page it came from, and stronger sources rate higher. Full methodology →
    Source

  • Neuroprotective effects of liraglutide against inflammation through the AMPK/NF-κB pathway in a mouse model of Parkinson's disease.

    95/100Rated 95/100Source typePeer-reviewed studyIndependent sourcesstill being verifiedEvery claim links to the page it came from, and stronger sources rate higher. Full methodology →
    Source

  • Protocol for a randomised controlled trial of the combined effects of the GLP-1 receptor agonist liraglutide and exercise on maintenance of weight loss and health after a very low-calorie diet.

    95/100Rated 95/100Source typePeer-reviewed studyIndependent sourcesstill being verifiedEvery claim links to the page it came from, and stronger sources rate higher. Full methodology →
    Source

  • Liraglutide attenuates type 2 diabetes mellitus-associated non-alcoholic fatty liver disease by activating AMPK/ACC signaling and inhibiting ferroptosis.

    95/100Rated 95/100Source typePeer-reviewed studyIndependent sourcesstill being verifiedEvery claim links to the page it came from, and stronger sources rate higher. Full methodology →
    Source

  • Liraglutide.

    95/100Rated 95/100Source typePeer-reviewed studyIndependent sourcesstill being verifiedEvery claim links to the page it came from, and stronger sources rate higher. Full methodology →
    Source

  • Liraglutide for Children 6 to <12 Years of Age with Obesity - A Randomized Trial.

    95/100Rated 95/100Source typePeer-reviewed studyIndependent sourcesstill being verifiedEvery claim links to the page it came from, and stronger sources rate higher. Full methodology →
    Source

  • Liraglutide Promotes Diabetic Wound Healing via Myo1c/Dock5.

    95/100Rated 95/100Source typePeer-reviewed studyIndependent sourcesstill being verifiedEvery claim links to the page it came from, and stronger sources rate higher. Full methodology →
    Source

  • Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study.

    95/100Rated 95/100Source typePeer-reviewed studyIndependent sourcesstill being verifiedEvery claim links to the page it came from, and stronger sources rate higher. Full methodology →
    Source

Timeline

History & Milestones

Key moments in Liraglutide’s research and regulatory timeline — sourced and dated.

  1. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight ManagementPublicationJul 2, 2015
    Related:Liraglutide
    95/100Rated 95/100Source typePeer-reviewed studyIndependent sourcesstill being verifiedEvery claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ source
  2. The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight lossPublicationOct 1, 2014
    Related:Liraglutide
    95/100Rated 95/100Source typePeer-reviewed studyIndependent sourcesstill being verifiedEvery claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ source
  3. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono)PublicationFeb 7, 2009
    Related:Liraglutide
    95/100Rated 95/100Source typePeer-reviewed studyIndependent sourcesstill being verifiedEvery claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ source

News

Latest on Liraglutide

Dated, sourced reporting that mentions Liraglutide.

ClinicalSep 21, 2026

CagriSema bests tirzepatide for weight loss in type 2 diabetes

Novo Nordisk announced topline results showing CagriSema, a fixed-dose combination of cagrilintide and semaglutide, produced greater weight loss than tirzepatide in adults with type 2 diabetes in the REIMAGINE 5 trial (12.4% vs. 9.1% at 60 weeks), while achieving noninferior HbA1c reductions. In the REDEFINE 9 trial, CagriSema led to 21% weight loss at 68 weeks in adults with overweight or obesity without diabetes. These are topline company-announced results from ongoing trial programs.

50/100Rated 50/100Source typeUnclassified sourceIndependent sourcesstill being verifiedEvery claim links to the page it came from, and stronger sources rate higher. Full methodology →Read →
ClinicalSep 17, 2026

Wegovy benefits consistent regardless of frailty level

A new analysis of the SELECT trial published in JAMA Cardiology found that semaglutide 2.4 mg (Wegovy) delivered cardiovascular benefits versus placebo consistently across all frailty levels. The most frail patients experienced the greatest quality-of-life improvements. The findings address concerns that GLP-1 therapies may be less safe or effective in frail populations.

50/100Rated 50/100Source typeUnclassified sourceIndependent sourcesstill being verifiedEvery claim links to the page it came from, and stronger sources rate higher. Full methodology →Read →
ResearchSep 14, 2026

Semaglutide linked to fewer exacerbations in asthma, COPD

An abstract presented at the 2026 European Respiratory Society International Congress links semaglutide use in patients with type 2 diabetes to fewer exacerbations in asthma (38% reduction) and COPD (21% reduction). Other GLP-1 receptor agonists like exenatide and dulaglutide also showed exacerbation reductions. The associations persisted regardless of weight or glycemic changes, suggesting possible direct lung anti-inflammatory effects.

50/100Rated 50/100Source typeUnclassified sourceIndependent sourcesstill being verifiedEvery claim links to the page it came from, and stronger sources rate higher. Full methodology →Read →
SafetyJun 25, 2026

Parker Waichman LLP Files Lawsuit on behalf of Ohio Resident Alleging Development of Irreversible Eye Condition, NAION, after taking Ozempic

Law firm Parker Waichman LLP has filed multiple lawsuits alleging patients developed NAION, an irreversible eye condition causing permanent vision loss, after taking Novo Nordisk's semaglutide drugs Ozempic and Wegovy. The lawsuits cite research linking semaglutide to increased NAION risk. The litigation alleges the manufacturer failed to adequately warn about the eye-injury risk.

60/100Rated 60/100Source typeSpecialist communityIndependent sourcesstill being verifiedEvery claim links to the page it came from, and stronger sources rate higher. Full methodology →Read →
RegulatoryJun 22, 2026

Wegovy, Zepbound: Guideline advises GLP-1s as first-line obesity drugs

The American College of Physicians has issued a new clinical guideline naming semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro) as preferred first-line drug treatments for adults with obesity, used alongside lifestyle changes. The recommendations were published in Annals of Internal Medicine and ranked other options like phentermine-topiramate, liraglutide, and naltrexone-bupropion below these GLP-1-based therapies. The guideline emphasizes individualized decisions weighing benefits, harms, cost, and patient preferences, and is designated a 'living guideline' to be updated as evidence evolves.

72/100Rated 72/100Source typeEstablished referenceIndependent sourcesstill being verifiedEvery claim links to the page it came from, and stronger sources rate higher. Full methodology →Read →

See all Liraglutide news →

Wondering how Liraglutide pricing compares across suppliers? Our original market data shows the full picture.

See the State of the Peptide Market 2026 →

Related on The Health Stacks

Explore by goal

GLP-1 & Metabolic Peptides

Related peptides

SemaglutideTirzepatideExenatideRetatrutideMOTS-c

Compare

Liraglutide vs Semaglutide Liraglutide vs Tirzepatide Liraglutide vs Exenatide

Free: The Peptide Stack Cheat-Sheet

The most-used peptide combinations, what the research actually says, and where to buy — one page, one email.

No spam. Unsubscribe anytime.